| 1 |
29504299 | Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis. | 2018 Apr |
1 |
| 2 |
27914464 | Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals. | 2016 Nov |
2 |
| 3 |
24444338 | Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. | 2014 Jul |
1 |
| 4 |
23831137 | Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. | 2013 Sep 30 |
3 |
| 5 |
22013146 | Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. | 2012 May |
7 |
| 6 |
22703536 | Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. | 2012 Jun 15 |
1 |
| 7 |
20445436 | Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. | 2010 May |
1 |
| 8 |
20524007 | Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta. | 2010 Oct |
1 |
| 9 |
19278300 | Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b. | 2009 Apr |
1 |
| 10 |
19465447 | High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. | 2009 Aug |
1 |
| 11 |
19667211 | Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. | 2009 Oct |
3 |
| 12 |
19884577 | Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. | 2009 Nov 3 |
1 |
| 13 |
17911184 | In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. | 2008 Jan |
2 |
| 14 |
17986500 | MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. | 2008 Jun |
1 |
| 15 |
17986510 | Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. | 2008 Mar |
1 |
| 16 |
18081914 | MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. | 2008 Jul |
2 |
| 17 |
18426595 | Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study. | 2008 Apr 21 |
3 |
| 18 |
18505772 | Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? | 2008 Jul |
4 |
| 19 |
19094453 | Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status. | 2008 Nov-Dec |
2 |
| 20 |
17389300 | Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. | 2007 Mar 27 |
3 |
| 21 |
17439886 | Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. | 2007 Mar |
2 |
| 22 |
17457510 | Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. | 2007 Jul |
1 |
| 23 |
17548440 | Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? | 2007 Jun |
2 |
| 24 |
17662004 | Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. | 2007 Aug |
1 |
| 25 |
17784815 | Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. | 2007 Aug |
1 |
| 26 |
16466595 | The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. | 2006 Feb |
1 |
| 27 |
15184610 | Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. | 2004 Jun 8 |
4 |
| 28 |
15253685 | Neutralizing antibodies to multiple sclerosis treatments. | 2004 Jun |
2 |
| 29 |
15264109 | Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. | 2004 Jun |
1 |
| 30 |
15314118 | Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. | 2004 Sep |
1 |
| 31 |
8857714 | Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. | 1996 Oct |
1 |